St. Jude Medical Announces US Launch And First Commercial Implants Of DRG Stimulation Therapy
St. Jude Medical, Inc., a global medical device company, recently announced the U.S. launch and first post-approval implants of the St. Jude Medical AxiumNeurostimulator System for dorsal root ganglion (DRG) stimulation to treat patients with chronic pain that has been hard to control with traditional spinal cord stimulation (SCS). (Source: Medical Design Online News)
Source: Medical Design Online News - April 12, 2016 Category: Medical Equipment Source Type: news
MassDevice.com +5 | The top 5 medtech stories for April 11, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Grifols puts up $100m for a 49% stake in Interstate Blood Bank
Grifols said that it agreed to pay $100 million for a 49% stake in plasma collector Interstate Blood Bank.
The deal includes an option to buy the remaining 51% for ...
Source: Mass Device - April 11, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
St. Jude Medical’s Axium chronic pain device makes its U.S. debut
St. Jude Medical (NYSE:STJ) today announced the U.S. debut of its Axium neurostimulator system, after the device won FDA approval in February for treating chronic pain.
The 1st patients were implanted in West Virginia and California with the Axium device, which uses dorsal root ganglion stimulation to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome, St. Jude said. The Axium is slated to be implanted in 25 states in the coming weeks, with 100 procedures due in the 1st month after launch, the Little Canada, Minn.-based company said.
“Si...
Source: Mass Device - April 11, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Neuromodulation/Neurostimulation Pain Management Wall Street Beat St. Jude Medical Source Type: news
St. Jude Medical Announces US Launch and First Commercial Implants of DRG Stimulation Therapy
Availability of the dorsal root ganglion (DRG) therapy represents an important milestone in the treatment of chronic intractable pain conditions due to complex regional pain syndrome I and II
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. ... Devices, Neurology, Product LaunchSt. Jude Medical, dorsal root ganglion, Axium , Neurostimulator, DRG therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2016 Category: Pharmaceuticals Source Type: news
Medical News Today: Glaucoma treatment expected to improve with new stem cell method
By devising a way to produce retinal ganglion cells from stem cells derived from individual patients, researchers hope to improve personalized treatments for glaucoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 23, 2016 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Ganglion Block Beats Blood Patch for Dural Puncture HeadacheGanglion Block Beats Blood Patch for Dural Puncture Headache
This approach should be the first-line therapy for obstetric patients experiencing postdural puncture headache, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 23, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
St. Jude Gains FDA Approval For Cardiac Pacing, Neurostimulation Technologies
The FDA has approved two new technologies that expand St. Jude Medical’s portfolio for cardiac resynchronization therapy (CRT) and neurostimulation in the U.S. market. St. Jude announced that its MultiPoint Pacing (MPP) technology would be added to the company’s Quadra CRT device offerings in the beginning of 2016, and that the Axium Neurostimulator System was approved for dorsal root ganglion (DRG) stimulation for patients with chronic pain in their lower limbs. (Source: Medical Design Online News)
Source: Medical Design Online News - February 18, 2016 Category: Medical Equipment Source Type: news
St. Jude wins FDA green light for Axium chronic pain device
St. Jude Medical (NYSE:STJ) said today it won FDA premarket approval for its Axium neurostimulator system using dorsal root ganglion stimulation.
The device from St. Paul, Minn.-based St. Jude is designed to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome.
“The approval of St. Jude Medical’s DRG neurostimulation system represents an exciting new option for me to deploy in the fight against the focal and intractable chronic pain syndromes facing my patients every day. For the large and growing numbers of under-treated patients suffering fro...
Source: Mass Device - February 17, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Neurological Neuromodulation/Neurostimulation St. Jude Medical Source Type: news
Video shows man popping a large ganglion cyst on his arm with a PIN
WARNING: GRAPHIC CONTENT. The man, known only as Jason, from Vancouver, cries in pain as he hammers the pin into his ganglion cyst. Reams of clear, sticky jelly ooze out. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2016 Category: Consumer Health News Source Type: news
Quantifying Spiral Ganglion Neurite and Schwann Behavior on Micropatterned Polymer Substrates
The first successful in vitro experiments on the cochlea were conducted in 1928 by Honor Fell (Fell, Arch Exp Zellforsch 7(1):69–81, 1928). Since then, techniques for culture of this tissue have been refined, and dissociated primary culture of the spiral ganglion has become a widely accepted in vitro model for studying nerve damage and regeneration in the cochlea. Additionally, patterned substrates have been developed that facilitate and direct neural outgrowth. A number of automated and semi-automated methods for quantifying this neurite outgrowth have been utilized in recent years (Zhang et al., J Neurosci Methods ...
Source: Springer protocols feed by Molecular Medicine - January 1, 2016 Category: Molecular Biology Source Type: news
Retinal nerve cells grown in the lab
A method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain, has been discovered by researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 30, 2015 Category: Science Source Type: news
Researchers grow retinal nerve cells in the lab
(Johns Hopkins Medicine) Johns Hopkins researchers have developed a method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2015 Category: Global & Universal Source Type: news
Neuron Astrocyte Glial Markers
Potent and Frequently Published!We have a stout catalog of Neuron-Astrocyte and Glial Markers.They are widely used and frequently published. Here're some recent examples:Mouse Monoclonal GFAP: Chelsea M. Larabee, Constantin Georgescu, Jonathan D. Wren and Scott M. Plafke. Expression profiling of the ubiquitin conjugating enzyme UbcM2 in murine brain reveals modest age-dependent decreases in specific neurons. BMC Neuroscience201516:76 DOI: 10.1186/s12868-015-0194-y© Larabee et al. 2015.Image: Mixed neuron-glial cultures stained with Mouse Monoclonal GFAP, and Chicken Polyclonal Neurofilament-NF-L (green). The GFAP antibody...
Source: Neuromics - November 28, 2015 Category: Neuroscience Tags: Astrocyte-Glial-Neuron Co-cultures GFAP Antibody Immunfluorescence immunoblotting Immunohistochemistry Neurofilament Markers Neuron Markers Source Type: news
Staining Neurons and 3-D
In this study researchers use our Tuj-1/Beta Tubulin Antibody to stain neurons in 3-D Cultures: Gaoying Sun, Wenwen Liu, Zhaomin Fan, Daogong Zhang, Yuechen Han, Lei Xu1, Jieyu Qi, Shasha Zhang, Bradley T. Gao, Xiaohui Bai,Jianfeng Li,Renjie Chai, Haibo Wang. The three-dimensional culture system with matrigel and neurotrophic factors preserves the structure and function of spiral ganglion neuron in vitro...Tuj-1-β-tubulin (1:1000, Neuromics, USA)... Images: Morphology of the SGNs growth cone cultured in 2D and 3D systems. Phalloidin, green; β-tubulin, red.I will continue to post positive developments concerning use of ou...
Source: Neuromics - November 20, 2015 Category: Neuroscience Tags: 3-D Cell based Assays 3-D Cell Culturing Immunofluorescence Neurons Tuj 1 (Neuron-specific class III beta-tubulin) antibody Tuj 1 antibody Tuj-1 antibodies Source Type: news
Subretinal Implant Restores Sight in Retinitis PigmentosaSubretinal Implant Restores Sight in Retinitis Pigmentosa
Almost three-quarters of patients blinded by retinitis pigmentosa were able to localize or identify objects after receiving a subretinal implant that stimulates ganglion cells. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 19, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
